Regeneron Pharmaceuticals (REGN)

$700.33 +4.31 (0.62%)
Market Cap 76.09B
Revenue (ttm) 14.20B
Net Income (ttm) 4.41B
EPS (ttm) N/A
PE Ratio 17.53
Forward PE 19.38
Profit Margin 31.07%
Debt to Equity Ratio 0.07
Volume 727,400
Avg Vol 911,626
Day's Range N/A - N/A
Shares Out 109.33M
Stochastic %K 70%
Beta 0.08
Analysts Strong Sell
Price Target $970.84

Latest News on REGN

Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman

Feb 21, 2025, 1:30 PM EST - 1 day ago

Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman

REGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025

Feb 18, 2025, 7:53 PM EST - 4 days ago

REGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025

Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens Berman

Feb 18, 2025, 12:45 PM EST - 4 days ago

Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens Berman

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

Feb 18, 2025, 12:59 AM EST - 5 days ago

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

Why Regeneron's Price May Soon Break Out

Feb 16, 2025, 9:54 PM EST - 6 days ago

Why Regeneron's Price May Soon Break Out

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

Feb 16, 2025, 9:39 AM EST - 6 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman

Feb 14, 2025, 12:19 PM EST - 8 days ago

Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman

Regeneron Announces Investor Conference Presentations

Feb 11, 2025, 4:05 PM EST - 11 days ago

Regeneron Announces Investor Conference Presentations

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

Feb 8, 2025, 5:40 PM EST - 14 days ago

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

Feb 8, 2025, 3:55 PM EST - 14 days ago

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

Regeneron Is Playing Defense With Capital Allocation

Feb 5, 2025, 1:10 PM EST - 17 days ago

Regeneron Is Playing Defense With Capital Allocation

Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings

Feb 5, 2025, 7:45 AM EST - 17 days ago

Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings

Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit - Hagens Berman

Feb 4, 2025, 7:15 PM EST - 18 days ago

Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit - Hagens Berman

Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025

Feb 4, 2025, 2:35 PM EST - 18 days ago

Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025

Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program

Feb 4, 2025, 12:02 PM EST - 18 days ago

Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2024 Earnings Call Transcript

Feb 4, 2025, 11:34 AM EST - 18 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2024 Earnings Call Transcript

Regeneron beats quarterly estimates on eczema drug demand; launches dividend program

Feb 4, 2025, 8:15 AM EST - 18 days ago

Regeneron beats quarterly estimates on eczema drug demand; launches dividend program

Regeneron's earnings boosted by demand for blockbuster eye drug Eylea

Feb 4, 2025, 8:03 AM EST - 18 days ago

Regeneron's earnings boosted by demand for blockbuster eye drug Eylea

Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion

Feb 4, 2025, 6:30 AM EST - 18 days ago

Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion

Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN

Feb 3, 2025, 5:45 AM EST - 19 days ago

Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

Jan 29, 2025, 10:57 AM EST - 24 days ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals